Clinical Trial Update: Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase II trial evaluates re-challenge with pembrolizumab as second- or later-line therapy in patients with advanced Non-small cell lung cancer. The study is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Spanish Lung Cancer Group | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-03-24